Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.

Genetically engineered mouse models in oncology research and cancer medicine

Open access
Kersten, Kelly, de Visser, Karin E, van Miltenburg, Martine H, Jonkers, Jos · 2017 · EMBO Molecular Medicine

Abstract

Genetically engineered mouse models (GEMMs) have contributed significantly to the field of cancer research. In contrast to cancer cell inoculation models, GEMMs develop de novo tumors in a natural immune‐proficient microenvironment. Tumors arising in advanced GEMMs closely mimic the histopathological and molecular features of their human counterparts, display genetic heterogeneity, and are able to spontaneously progress toward metastatic disease. As such, GEMMs are generally superior to cancer cell inoculation models, which show no or limited heterogeneity and are often metastatic from the start. Given that GEMMs capture both tumor cell‐intrinsic and cell‐extrinsic factors that drive de novo tumor initiation and progression toward metastatic disease, these models are indispensable for preclinical research. GEMMs have successfully been used to validate candidate cancer genes and drug targets, assess therapy efficacy, dissect the impact of the tumor microenvironment, and evaluate mechanisms of drug resistance. In vivo validation of candidate cancer genes and therapeutic targets is further accelerated by recent advances in genetic engineering that enable fast‐track generation and fine‐tuning of GEMMs to more closely resemble human patients. In addition, aligning preclinical tumor intervention studies in advanced GEMMs with clinical studies in patients is expected to accelerate the development of novel therapeutic strategies and their translation into the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201606857

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Applications of GEMMs in basic cancer research and translational oncology
Figure 1 Applications of GEMMs in basic cancer research and translational oncologyCC BY · PubMed Central
Figure 2 Schematic overview of transplantation‐based mouse models and germline GEMMs (A) Cancer cell line transplantation models are based on (orthotopic) inoculation of cultured human or mouse cancer cells in immunodeficient or syngeneic mice, respectively. (B) Patient‐derived tumor xenograft models or GEMM‐derived tumor allograft models are based on direct (orthotopic) implantation of human or mouse tumor fragments in immunodeficient or syngeneic mice, respectively. (C) In oncomice, de novo tumorigenesis is induced by transgenic expression of an oncogene (ONC) from a tissue‐specific promoter. (D) In tumor suppressor gene (TSG) knockout mice, de novo tumorigenesis is induced by germline inactivation of a TSG. (E, F) In conditional GEMMs, de novo formation of sporadic tumors is induced by tissue‐specific Cre‐loxP‐mediated inactivation of conditional TSG alleles (E) and/or activation of conditional oncogenes (F). Tissue‐specific expression of the Cre‐recombinase is achieved by crossbreeding with Cre transgenic mice, tamoxifen‐inducible Cre‐ERT transgenic mice, or by local administration of Cre‐encoding lenti‐ or adenoviruses. (G, H) Oncogene addiction can be studied using GEMMs with tamoxifen‐ or doxycycline‐inducible gene expression. (G) Administration of tamoxifen to transgenic mice carrying an oncogene‐ERT (ONC‐ERT) fusion will induce tumors that may undergo no, temporal, or durable regression upon tamoxifen withdrawal. (H) Similar studies can be performed by administration of doxycycline to bi‐transgenic mice with tissue‐specific expression of the reverse tetracycline‐controlled transactivator (rtTA) and carrying an oncogene or shRNA under transcriptional control of a tetracycline response element (TRE).
Figure 2 Schematic overview of transplantation‐based mouse models and germline GEMMs (A) Cancer cell line transplantation models are based on (orthotopic) inoculation of cultured human or mouse cancer cells in immunodeficient or syngeneic mice, respectively. (B) Patient‐derived tumor xenograft models or GEMM‐derived tumor allograft models are based on direct (orthotopic) implantation of human or mouse tumor fragments in immunodeficient or syngeneic mice, respectively. (C) In oncomice, de novo tumorigenesis is induced by transgenic expression of an oncogene (ONC) from a tissue‐specific promoter. (D) In tumor suppressor gene (TSG) knockout mice, de novo tumorigenesis is induced by germline inactivation of a TSG. (E, F) In conditional GEMMs, de novo formation of sporadic tumors is induced by tissue‐specific Cre‐loxP‐mediated inactivation of conditional TSG alleles (E) and/or activation of conditional oncogenes (F). Tissue‐specific expression of the Cre‐recombinase is achieved by crossbreeding with Cre transgenic mice, tamoxifen‐inducible Cre‐ERT transgenic mice, or by local administration of Cre‐encoding lenti‐ or adenoviruses. (G, H) Oncogene addiction can be studied using GEMMs with tamoxifen‐ or doxycycline‐inducible gene expression. (G) Administration of tamoxifen to transgenic mice carrying an oncogene‐ERT (ONC‐ERT) fusion will induce tumors that may undergo no, temporal, or durable regression upon tamoxifen withdrawal. (H) Similar studies can be performed by administration of doxycycline to bi‐transgenic mice with tissue‐specific expression of the reverse tetracycline‐controlled transactivator (rtTA) and carrying an oncogene or shRNA under transcriptional control of a tetracycline response element (TRE).CC BY · PubMed Central
Figure 3 Schematic overview of non‐germline GEMMs (A) Embryonic stem cell (ESC)‐derived non‐germline GEMMs. ESCs from wild‐type mice or established GEMMs can be used to introduce single or multiple mutations using CRISPR/Cas9‐based gene editing and/or mutant alleles using recombinase‐mediated cassette exchange (RMCE). The resulting ESCs can be injected into host blastocysts, which are implanted into pseudo‐pregnant females to produce chimeric mice. (B, C) CRISPR/Cas9‐based non‐germline GEMMs. CRISPR/Cas9‐mediated in situ gene editing can be achieved by local administration of sgRNA‐encoding lentiviruses in transgenic mice with tissue‐specific Cas9 expression (B), or by local administration of lentiviruses that encode both Cas9 and sgRNA in wild‐type mice (C). The latter approach may require immunodeficient or Cas9‐tolerant mice to avoid Cas9‐specific immune responses.
Figure 3 Schematic overview of non‐germline GEMMs (A) Embryonic stem cell (ESC)‐derived non‐germline GEMMs. ESCs from wild‐type mice or established GEMMs can be used to introduce single or multiple mutations using CRISPR/Cas9‐based gene editing and/or mutant alleles using recombinase‐mediated cassette exchange (RMCE). The resulting ESCs can be injected into host blastocysts, which are implanted into pseudo‐pregnant females to produce chimeric mice. (B, C) CRISPR/Cas9‐based non‐germline GEMMs. CRISPR/Cas9‐mediated in situ gene editing can be achieved by local administration of sgRNA‐encoding lentiviruses in transgenic mice with tissue‐specific Cas9 expression (B), or by local administration of lentiviruses that encode both Cas9 and sgRNA in wild‐type mice (C). The latter approach may require immunodeficient or Cas9‐tolerant mice to avoid Cas9‐specific immune responses.CC BY · PubMed Central
Figure 4 Applications of mouse models in metastasis research This overview summarizes the utility of different preclinical mouse models of experimental and spontaneous metastasis to study the different steps of the metastatic cascade. Conventional GEMMs represent oncomice and TSG knockout mice. Next‐generation GEMMs represent conditional mouse models that are genetically engineered to accurately mimic sporadic human cancer. For some models, the utility for studying specific steps in the metastatic cascade has yet to be determined, as indicated by a question mark. Moreover, several studies have shown that components of the adaptive immune system contribute to the various steps of the metastatic cascade. These aspects cannot be studied in models based on xenografting of human cancer cells or tumor fragments in immunodeficient hosts (indicated by an asterisk). To circumvent this, humanized mice can be used as hosts.
Figure 4 Applications of mouse models in metastasis research This overview summarizes the utility of different preclinical mouse models of experimental and spontaneous metastasis to study the different steps of the metastatic cascade. Conventional GEMMs represent oncomice and TSG knockout mice. Next‐generation GEMMs represent conditional mouse models that are genetically engineered to accurately mimic sporadic human cancer. For some models, the utility for studying specific steps in the metastatic cascade has yet to be determined, as indicated by a question mark. Moreover, several studies have shown that components of the adaptive immune system contribute to the various steps of the metastatic cascade. These aspects cannot be studied in models based on xenografting of human cancer cells or tumor fragments in immunodeficient hosts (indicated by an asterisk). To circumvent this, humanized mice can be used as hosts.CC BY · PubMed Central
Figure 5 Applications of mouse models in cancer drug development Development of novel treatment strategies in oncology requires preclinical studies in mouse cancer models to identify and validate novel cancer drivers and therapeutic targets, to determine in vivo drug pharmacokinetics and pharmacodynamics (PK/PD), and to evaluate in vivo anti‐cancer efficacy of novel therapeutics. When promising preclinical results are obtained, the tolerability and anti‐cancer efficacy of these drugs are evaluated in human patients in phase I–III clinical trials. A proportion of patients will show poor response due to intrinsic or acquired resistance, which may be studied mechanistically in preclinical mouse models to identify response biomarkers and combination therapies to prevent or overcome resistance. The close alignment of mouse studies and human clinical trials will lead to better patient stratification, identification of novel biomarkers, and development of optimal combination therapies, culminating in improved cancer patient care.
Figure 5 Applications of mouse models in cancer drug development Development of novel treatment strategies in oncology requires preclinical studies in mouse cancer models to identify and validate novel cancer drivers and therapeutic targets, to determine in vivo drug pharmacokinetics and pharmacodynamics (PK/PD), and to evaluate in vivo anti‐cancer efficacy of novel therapeutics. When promising preclinical results are obtained, the tolerability and anti‐cancer efficacy of these drugs are evaluated in human patients in phase I–III clinical trials. A proportion of patients will show poor response due to intrinsic or acquired resistance, which may be studied mechanistically in preclinical mouse models to identify response biomarkers and combination therapies to prevent or overcome resistance. The close alignment of mouse studies and human clinical trials will lead to better patient stratification, identification of novel biomarkers, and development of optimal combination therapies, culminating in improved cancer patient care.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 168 references

Cited by

See all 569

Metadata

Authors
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J.
Affiliations
The Netherlands Cancer Institute (NL)
Corresponding author
Jonkers, Jos
Venue
EMBO Molecular Medicine
Published
2016-12-27
Volume
9
Issue
2
Pages
137-153
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2563661701
Cited by
502
References
168
Citations by year
2026: 53 · 2025: 47 · 2024: 52 · 2023: 69 · 2022: 75 · 2021: 61 · 2020: 59 · 2019: 39 · 2018: 32 · 2017: 13 · 2016: 2
FWCI
2.88
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Dutch Cancer Society (5220, 6532, 7048, 7589, 7835, 7877)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (93512009, 91814643, National Roadmap grant for Large‐scale Research Facilities)
  • Worldwide Cancer Research (14‐0288)
  • European Union Seventh Framework Program (260791, 312325, MCA‐ITN 317445)
  • European Research Council (319661, 615300)
  • Beug Foundation for Metastasis Research
  • EMBO Young Investigator
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
genetically engineered mouse models, cancer research, tumor microenvironment, metastasis, preclinical cancer models, drug target validation, drug resistance, tumor heterogeneity, translational oncology
MeSH terms
Animals, Disease Models, Animal, Humans, Medical Oncology, Neoplasms, Animals, Genetically Modified, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetically engineered mouse models in oncology research and cancer medicine. https://app.cochat.ai/papers/10.15252/emmm.201606857
The paper
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017). Genetically engineered mouse models in oncology research and cancer medicine. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201606857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.